Page last updated: 2024-11-07

diglycyl-histidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

diglycyl-histidine: tripeptide complexed with cupric ion designed to mimic specific Cu(II) transport site of ascorbate on albumin molecule; glycylglycylhistamine is An amine derived by enzymatic decarboxylation of histidine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6992501
CHEBI ID163695
SCHEMBL ID483987
MeSH IDM0112319

Synonyms (23)

Synonym
diglycyl-histidine
gly-gly-his
glycylglycyl-l-histidine
nsc-334195
nsc334195
7451-76-5
(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-(1h-imidazol-5-yl)propanoic acid
CHEBI:163695
nsc 334195
glycyl-glycyl-histidine
AKOS010420476
SCHEMBL483987
(s)-2-(2-(2-aminoacetamido)acetamido)-3-(1h-imidazol-4-yl)propanoic acid
h-gly-gly-his-oh
h-gly-gly-his-oh, aldrichcpr
mfcd00079323
glycyl-glycyl-l-histidine
A865872
(2s)-2-[2-(2-aminoacetamido)acetamido]-3-(1h-imidazol-4-yl)propanoic acid
AS-57022
CS-W014586
HY-W013870
AKOS040744581
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oligopeptideA peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (16.13)18.7374
1990's9 (29.03)18.2507
2000's8 (25.81)29.6817
2010's8 (25.81)24.3611
2020's1 (3.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.03%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (96.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]